Completed PHASE4 INTERVENTIONAL 1-arm NCT02948777

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Sponsor: Göteborg University

Interventions Evolocumab

Updated 8 times since 2017 Last updated: Oct 28, 2021 Started: Oct 31, 2016 Primary completion: Jun 30, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02948777, this PHASE4 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Göteborg University, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Nov 2021 — Dec 2021 [monthly]

Completed PHASE4
Jan 2021 — Nov 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Sep 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Feb 2017 — Sep 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Göteborg University
Marja-Riitta Taskinen

Data source: Clinical Research Institute HUCH Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland